JONATHAN J. PALY, D.O.

Plain English
This study compared two types of radiation therapy—proton therapy (IMPT) and traditional photon therapy (IMRT)—for patients with advanced oropharyngeal cancer. Researchers found that, after three years, 82.5% of patients receiving proton therapy were free of disease progression, which was similar to the 83.0% rate for those receiving photon therapy. Proton therapy also improved overall survival (90.9% vs. 81.0%) and caused fewer severe side effects. Who this helps: This helps patients with oropharyngeal cancer by providing a less harmful treatment option.

Plain English
This study looked at two patients with a rare type of cancer in the lacrimal sac, which is the area around the tear ducts, and both patients were positive for certain types of HPV (HPV16 and HPV33). Researchers monitored the levels of circulating tumor DNA (ctDNA) from these patients before, during, and after their treatment with chemotherapy and radiation, and found that using ctDNA tracking can effectively help detect and monitor the cancer's response to treatment. This finding is important because it supports the use of ctDNA as a non-invasive way to keep an eye on treatment success, which could guide future care for patients with this type of cancer. Who this helps: Patients with lacrimal sac squamous cell carcinoma and their doctors.

Plain English
Researchers examined a blood test that detects tumor DNA in patients with a specific type of head and neck cancer that doesn't involve HPV. They found that when the test showed positive results after treatment, it indicated a higher chance of cancer recurrence and lower survival rates. This finding is important because it suggests that this blood test could help doctors identify patients at greater risk after treatment, potentially leading to more tailored monitoring and care.

Plain English
Researchers studied a blood test that detects tiny amounts of tumor DNA in patients with a specific type of throat cancer that is not linked to HPV. They found that when this DNA was present, patients were more likely to experience a recurrence of their cancer and had a shorter survival time. This finding is important because it suggests that this blood test could help doctors predict outcomes and make better treatment decisions for patients with this type of cancer.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
Researchers developed a highly sensitive blood test that detects tiny amounts of HPV cancer DNA left in patients after surgery for HPV-related head and neck cancer. They found that patients whose blood still contained this cancer DNA had much worse outcomes—only 60% stayed cancer-free for 2 years compared to 100% of patients with no detectable DNA—and this blood test was better at predicting who would relapse than current methods doctors use. The test could also spot cancer coming back up to 17 months before it shows up on scans or causes symptoms, giving doctors an early warning system to decide whether patients need additional treatment like chemotherapy or radiation.

Plain English
This study looked at how a new online education program for radiation therapy improved knowledge and confidence among medical professionals in low- and middle-income countries, specifically in Africa and Latin America. After taking part in 27 online sessions, participants showed a significant increase in their knowledge from 47.9% to 89.6%, and their confidence also improved in several important areas, indicating the program was effective and participants were eager to use what they learned in their clinics. Who this helps: This benefits doctors and medical staff working in radiation therapy in low-resource settings.

Plain English
This study examined a rare type of brain tumor called meningioma that appeared as a large lump in the neck of a 26-year-old woman. The researchers found that the fine needle aspiration (FNA) test, which is commonly used to identify lumps, showed signs of the tumor but also revealed complexities due to its unusual features, including a specific protein loss. These findings matter because they highlight the difficulties in diagnosing neck masses correctly and emphasize the need for more tests to ensure accurate identification of such tumors. Who this helps: This helps doctors and medical professionals who evaluate neck lumps in patients.

Plain English
This study looked at how effective stereotactic radiosurgery (SRS) is for patients with multiple brain tumors caused by specific types of non-small cell lung cancer (NSCLC) driven by EGFR and ALK. Researchers analyzed data from 89 patients who received SRS for at least four brain metastases and found that the average survival time was about 24 months overall, with 21 months for EGFR patients and 33 months for ALK patients. The study also noted that after treatment, most patients (about 74%) did not need additional whole-brain radiotherapy, indicating that SRS can be a beneficial treatment option for those with multiple brain tumors from these cancer types. Who this helps: This helps patients with EGFR or ALK-driven non-small cell lung cancer and their doctors by providing evidence for effective treatment options.

Plain English
This study looked at how prostate-specific antigen (PSA) levels change in patients with low- and intermediate-risk prostate cancer after they receive different types of radiation therapy. Out of 1,042 patients, those treated with more aggressive methods (like brachytherapy) had higher and faster drops in their PSA levels, with 50% of them reaching a low PSA level of 0.5 ng/mL or less, compared to only 23% and 33% of those receiving other treatments. This information is important because understanding PSA changes helps doctors evaluate how well the treatment is working and monitor for any signs of cancer returning. Who this helps: This helps patients undergoing radiation therapy for prostate cancer and their doctors.

Plain English
This study looked at how two types of radiation therapy—proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT)—affect patients with early-stage prostate cancer over time. Researchers followed 1,850 patients treated between 1998 and 2018 and found that most people experienced very little long-term side effects: 56.6% had no urinary issues and 74.4% had no gastrointestinal problems. There was no significant difference in side effects between the two treatment methods, suggesting that both are safe options for patients. Who this helps: This benefits patients with early-stage prostate cancer and their doctors by providing information on safe treatment options.

Plain English
This study looked at how different radiation treatments for prostate cancer—specifically stereotactic body radiation therapy (SBRT), high dose rate (HDR), and low dose rate (LDR) brachytherapy—affected patients' quality of life over time. It found that men who received SBRT and HDR had better urinary health outcomes compared to those who received LDR, with worse overall urinary symptoms reported after LDR treatment. These findings are important because they can help doctors choose the best treatment options to improve the quality of life for their patients. Who this helps: This helps patients with prostate cancer and their doctors by providing information on which treatment may lead to a better quality of life.

Plain English
This study looked at a new type of radiation therapy called pulsed low-dose rate radiation therapy to treat patients needing pelvic reirradiation. The researchers found that this method led to strong control of tumor growth with minimal harm to surrounding healthy tissue, demonstrating better safety and effectiveness. Specifically, patients experienced low toxicity, making it a promising option for treatment. Who this helps: This benefits patients undergoing treatment for pelvic tumors, offering them a safer and more effective therapy option.

Plain English
The study looked at how a mentorship program for junior faculty in academic medicine affected their job satisfaction and career success from 2009 to 2016. It found that after joining the program, 47% of mentees moved into senior faculty roles compared to just 13% of those who didn’t have mentors. Mentees were also more likely to receive funding and promotions, especially if they started as Instructors. This matters because strong mentorship can help junior faculty achieve greater career success and contribute to a positive work environment. Who this helps: This helps junior faculty and the medical institutions they work for.

Plain English
This study looked at the long-term quality of life for prostate cancer patients 14 to 18 years after they received treatment, comparing three main treatment methods: surgery, radiation therapy, and brachytherapy. The researchers found that patients who had surgery reported worse urinary incontinence and sexual function, while those who received radiation therapy experienced declines across all areas of health. Understanding these outcomes is important because it helps patients make better choices about their treatment options based on potential long-term effects. Who this helps: This helps prostate cancer patients making treatment decisions.

Plain English
This study looked at how patients with early-stage testicular seminoma (specifically stages IIA and IIB) are treated and their survival outcomes. Researchers found that 38.5% of 1,885 patients received chemotherapy while 61.5% received radiation therapy (RT). The survival rate after five years was 99.4% for those treated with orchiectomy (surgery to remove the testicle) and RT versus 91.2% for those who received surgery and chemotherapy for stage IIA, showing that radiation is the better option for these patients. Who this helps: This benefits patients diagnosed with clinical stage IIA/B seminoma by providing insights into better treatment options.

Plain English
This study looked at how stage I testicular seminoma, a type of testicular cancer, is being treated and how factors like race and insurance impact treatment choices. Over time, the number of patients who were simply observed after surgery rose from 23.7% to 54%, while chemotherapy use increased from 1.5% to 16%, and radiotherapy usage dropped from 70.8% to 28.8%. This is important because it shows that treatment strategies are changing, and certain groups, like racial minorities and uninsured patients, tend to follow different paths in their treatment. Who this helps: This helps patients dealing with stage I testicular seminoma and their healthcare providers.

Plain English
This study looked at men with low-risk prostate cancer who were monitored over time without immediate treatment, a method known as active surveillance. Out of 469 men, 77% did not require any treatment after five years, and 62% continued without treatment after ten years, while cancer-specific survival remained at 100% throughout this period. This is important because it shows that many men can safely avoid aggressive treatments, which often have significant side effects, without compromising their chances of survival over a decade. Who this helps: This benefits patients with low-risk prostate cancer and their doctors by providing reassurance about monitoring instead of immediate treatment.

Plain English
This study looked at how talking to a medical oncologist affects treatment choices for men with low-risk prostate cancer. Researchers found that men who consulted with an oncologist were more likely to choose active surveillance (watching the cancer closely instead of immediate treatment), with 37% opting for this approach compared to only 21% who didn't consult an oncologist. This matters because it helps prevent unnecessary treatments in men with low-risk cancer and shorter life expectancies. Who this helps: Patients with low-risk prostate cancer and limited life expectancy.

Plain English
This study looked at how effective a special type of radiation therapy, given during surgery, is for patients with advanced or recurrent kidney cancer. Researchers tracked 98 patients from multiple hospitals and found that 5 years after treatment, 37% of patients with advanced cancer were still alive, while 55% of those with recurrent cancer survived. This is important because it shows that this approach might lead to better survival rates for patients with recurrent tumors compared to those who just had surgery without this treatment. Who this helps: This helps kidney cancer patients and their doctors by providing new treatment options.

Plain English
This study focused on the rising number of HIV-related cancers in Botswana and aimed to enhance cancer care through the BOTSOGO collaboration with local healthcare providers. The partnership introduced new treatment methods and improved care practices, benefiting both patients and healthcare staff. This model shows how academic institutions can effectively support countries facing high cancer rates and limited resources. Who this helps: Patients with HIV-related cancers and healthcare professionals in Botswana.

Plain English
This study looked at online information about proton beam therapy (PBT) for treating prostate cancer to see how reliable and accurate it is. Out of 50 websites reviewed, 37 provided the necessary information, but many had significant inaccuracies and varying levels of quality, even though 46% were patient support resources. It’s important for doctors to help patients understand this information better so they can make informed choices about their treatment. Who this helps: Patients considering proton therapy for prostate cancer.

Plain English
Researchers studied where cancerous lymph nodes are found in patients with seminoma, a type of testicular cancer, to improve radiation therapy. They examined scans from 90 patients and found that 145 cancerous nodes were primarily located in specific areas near the aorta: 84% in the para-aortic region, 9% in the common iliac region, and 7% in the pelvic region. This matters because the findings show that the cancer spreads in a smaller area than previously thought, allowing for more targeted radiation treatment that could reduce side effects. Who this helps: This helps seminoma patients by potentially improving their treatment outcomes and reducing radiation-related complications.

Plain English
The study looked at how different types of radiation therapy for localized prostate cancer—3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and proton beam therapy (PBT)—affected patients' quality of life related to bowel and urinary health. It found that at 2-3 months after treatment, patients receiving 3DCRT and IMRT reported significant bowel quality of life issues, while those receiving PBT did not. By 12 months, all groups reported some bowel problems, but PBT patients had urinary issues, highlighting that each treatment has unique side effects. Who this helps: This information helps patients and doctors choose the best radiation therapy option based on potential quality of life outcomes.

Plain English
This research focused on a treatment approach called trimodality therapy for patients with muscle-invasive bladder cancer, aiming to preserve the bladder. The study analyzed data from 325 patients, finding that their nomograms can predict how likely a patient is to respond completely to treatment, survive without cancer, and stay free of needing bladder removal surgery. Specifically, the models showed a moderate ability to predict outcomes, with an accuracy rate of 69% for complete response and 61% for survival rates. Who this helps: This benefits patients with muscle-invasive bladder cancer and their doctors by providing tailored predictions for treatment outcomes.

Plain English
This study looked at a new way of planning radiation treatment for prostate cancer using a method called multicriteria optimization (MCO). Researchers found that MCO plans were rated as significantly better than traditional plans by radiation oncologists, with reductions in harmful doses to nearby organs like the bladder and rectum. This is important because it means patients can receive effective treatment with fewer side effects. Who this helps: This helps prostate cancer patients by improving their treatment experience and reducing risks of complications.

Plain English
This study looked at how treating prostate cancer in a multidisciplinary clinic—where doctors from different specialties work together—affects patient care and treatment decisions. It found that patients considered low-risk choose "active surveillance" (a way to closely monitor the cancer without immediate treatment) more often in these settings. High patient satisfaction was also noted, and the collaborative approach helps reduce bias from individual doctors. Who this helps: This benefits patients with prostate cancer by providing better support and treatment choices.

Plain English
This study looked at how care models impact treatment decisions for men with very-low-risk prostate cancer, which is a type of cancer that is not expected to threaten their lives in the near future. Researchers found that 64% of patients who received care from a team of specialists opted for active surveillance—essentially monitoring the cancer instead of immediate treatment—compared to only 30% of those who saw individual doctors. This is important because it shows that having a group of doctors discuss a patient’s case together leads to better adherence to guidelines that recommend active surveillance, helping to avoid unnecessary treatments. Who this helps: This benefits men with very-low-risk prostate cancer and their doctors.

Plain English
This study looked at the long-term quality of life for men with localized prostate cancer who were treated with high-dose proton beam radiation. The research involved 95 men, and those who reported their outcomes over time showed that, after two years, there were small increases in bowel dysfunction and incontinence, along with more significant changes in sexual dysfunction. These findings are important because they help to understand how proton therapy affects daily life and can guide expectations for men receiving this treatment. Who this helps: This helps patients with prostate cancer by providing insights into the potential long-term effects of their treatment.

Plain English
This study examined whether a treatment method called combined-modality therapy (CMT) for muscle-invasive bladder cancer can provide long-term survival results similar to surgery, specifically radical cystectomy. Researchers at Massachusetts General Hospital followed 348 patients over an average of 7.7 years, finding that 72% of patients had a complete response to the therapy. The long-term survival rates were promising, with 5-year disease-specific survival at 64% and overall survival at 52%, demonstrating that CMT can effectively preserve the bladder while offering solid survival outcomes. Who this helps: This benefits patients with muscle-invasive bladder cancer who wish to avoid surgery.

Plain English
This study looked at using a new method of proton beam radiation therapy to treat prostate cancer, focusing on how to better protect the rectum during treatment. The researchers found that using "anterior-oriented" radiation fields significantly reduced the radiation dose to the rectal area compared to traditional treatment, with the rectal wall receiving only 6% of the prescribed dose with the new method versus 39% with the standard approach. This is important because it could lead to fewer side effects for patients while still effectively targeting the cancer. Who this helps: Patients undergoing prostate cancer treatment.

Plain English
This study focused on the complications that arise from salvage cystectomy, a procedure for bladder cancer patients who did not respond to earlier bladder-sparing treatments. Out of 91 patients who received salvage cystectomy, 69% experienced complications within 90 days, with 16% facing severe issues. Immediate cystectomy patients had a higher risk of heart-related complications (37%) compared to delayed cystectomy patients (15%), who faced more healing complications instead (35% versus 12%). Who this helps: This information is valuable for patients undergoing treatment for muscle-invasive bladder cancer and their doctors.

Plain English
This study looked at how willing patients with localized prostate cancer are to participate in a clinical trial comparing two types of radiation therapy: intensity-modulated radiotherapy (IMRT) and proton beam therapy (PBT). Out of 46 patients interviewed, 59% said they would definitely or probably join the trial, while 17% expressed they would definitely or probably not participate, primarily favoring PBT before their doctor visits. Understanding patients' willingness to participate in such trials is important because it helps researchers design studies that align with patient preferences and improve treatment comparisons. Who this helps: Patients with localized prostate cancer seeking the best treatment options.

Plain English
This study compared two types of radiation therapy—proton and photon—used in treating early-stage seminoma, a type of testicular cancer. Researchers found that proton therapy significantly reduces radiation exposure to important organs, cutting the dose by 46% to the stomach and 64% to the large intestine. This difference is important because it could prevent an estimated 300 additional cancers in every 10,000 men treated, improving long-term health outcomes. Who this helps: This benefits cancer patients, particularly those with early-stage seminoma.

Plain English
This study looked at how seeing multiple doctors at the same time, in a multidisciplinary clinic, affects the treatment choices for men with low-risk prostate cancer. The results showed that 43% of men who consulted at these clinics chose active surveillance, which is a watch-and-wait approach, compared to only 22% of those who saw individual doctors. This is important because it suggests that a team-based approach leads to less invasive treatments, which can improve patients' quality of life and reduce healthcare costs. Who this helps: This helps patients with low-risk prostate cancer.

Plain English
This study looked at a modified form of the prolactin receptor (PRL-R) in mice to see how it affected the development of mammary glands. Researchers found that the modified receptor caused the mammary glands of young mice to develop unusually, with excessive duct structures, but these mice failed to produce milk after giving birth. This is important because it shows how changes in hormone signaling can lead to problems with lactation, which affects the ability to nourish newborns. Who this helps: This research aids new parents, particularly mothers who may struggle with breastfeeding due to hormonal issues.

Plain English
This study looked at how mutations in placental hormones from sheep and cows affect their ability to work with certain receptors in the body. Researchers found that while these mutations reduced the hormones' ability to bind to receptors, they still managed to trigger biological activity nearly as effectively in other contexts. However, these changes significantly weakened their effectiveness when interacting with their specific receptors, resulting in a complete or partial loss of function. Who this helps: This helps researchers and doctors working with animal reproduction and fertility.

Plain English
This study looked at how the prolactin receptor (PRL-R) affects cell signaling that promotes cell growth and development. Researchers discovered that a specific part of the receptor actually slows down the process of activating a key pathway involved in these cellular responses. They found that both the MEK and PI3K pathways are needed for the activation, and the last part of the receptor appears to turn down the signal's strength, which might influence how cells respond to prolactin. Who this helps: This research benefits doctors and scientists studying hormone effects on cell growth, particularly in conditions related to prolactin.

Plain English
Researchers created a specific site in a gene that helps produce a milk protein in mice, which allowed the protein's production to be controlled by the hormone prolactin. They found that after making this change, the gene worked better in living mice, leading to a higher number of mice showing the desired protein during pregnancy. This matters because controlled production of important proteins could improve studies on milk production or treatments related to breastfeeding. Who this helps: This helps researchers and healthcare providers studying breastfeeding and related maternal health issues.

Plain English
This study examined how two specific parts of the prolactin receptor (a protein that helps regulate various biological processes) affect calcium levels in cells. Researchers found that when certain parts of the receptor were removed in specially altered cells, the usual increase in calcium wasn't observed. This matters because understanding how the prolactin receptor works could help develop targeted treatments for conditions influenced by this hormone, such as fertility issues or hormone-related cancers. Who this helps: Patients with hormone-related health conditions.

Plain English
This study focused on cloning and preparing a hormone from goat placenta called caprine placental lactogen (cPL). The researchers successfully produced large amounts of this hormone in bacteria, which were then purified to ensure they had the right form (over 98% pure with a weight of about 23 kDa). They found that cPL can bind to growth hormone receptors and prolactin receptors in various animals, which is important because this hormone has the potential to stimulate cell growth and milk production. Who this helps: This research benefits doctors and researchers studying hormone therapies and reproductive health in livestock and other animals.

Plain English
This study looked at how growth hormone (GH) affects calcium levels inside Chinese hamster ovary cells. Researchers found that when they added GH, about 54% of the cells experienced an increase in calcium, with the amount of increase varying significantly—some cells saw an increase of just 16 nanomoles per liter, while others reached an increase of 853 nanomoles per liter. This work is important because it shows that GH causes calcium levels to rise in two ways: by bringing calcium in from outside the cell and by releasing it from internal stores. Who this helps: This helps researchers and doctors understand how growth hormone affects cell function, potentially impacting treatments for hormone-related conditions.

Plain English
This study looked at the prolactin receptor, which is important for how the body responds to the hormone prolactin. Researchers created mutant versions of the receptor, finding that deleting a specific part (the S2 subdomain) allowed the receptor to work on its own, without needing prolactin. This discovery highlights the complexity of how this receptor functions and could lead to better understanding of hormone signaling in related diseases. Who this helps: This helps researchers and doctors working on hormonal therapies and conditions related to prolactin.

Plain English
The study looked at how prolactin, a hormone, affects calcium levels inside certain cells from Chinese hamsters that have been modified to have a lot of prolactin receptors. Researchers found that prolactin increases calcium levels significantly, with increases ranging from 300 to 1400 nM, and this rise happens in two ways: a quick response within 2 seconds and a slower response around 10 seconds. These findings are important because the increase in calcium can lead to various cellular activities like secretion and growth, which are crucial for processes like milk production. Who this helps: This helps researchers and doctors working on hormone-related therapies and conditions.

Plain English
This study looked at how prolactin, a hormone, and its receptor are taken into and broken down by specialized cells known as Chinese hamster ovary (CHO) cells. Researchers found that these cells could take in hormone at a rate of about 1 femtomole per hour and that the presence of the hormone significantly sped up the endocytosis process. This matters because understanding how prolactin receptors work can help in developing treatments for conditions affected by this hormone. Who this helps: Patients with conditions related to prolactin levels, such as those with prolactinomas or other hormonal disorders.

Plain English
This research studied the prolactin receptor (PRL-R) and how specific parts of its structure affect its ability to transmit signals inside cells. The scientists found that a specific segment of 23 amino acids in the receptor's cytoplasmic region is crucial for its function; without this segment, the receptor cannot operate effectively. This finding helps us understand how prolactin signaling works, which is important for many processes in the body, including lactation and reproductive health. Who this helps: This helps patients with hormonal imbalances and doctors treating related conditions.

Plain English
This study looked at how the prolactin receptor in mammary glands affects the production of milk proteins. Researchers found that when prolactin binds to its receptor, it causes an increase in calcium levels inside the cell and triggers specific chemical changes in a protein related to the prolactin receptor itself. This matters because understanding these processes helps clarify how milk production is controlled, which is important for improving lactation in various situations. Who this helps: This helps lactating women, dairy farmers, and researchers working on improving milk production.